Результаты поиска - Law, Steven
- Отображение 1 - 8 результаты of 8
-
1
-
2
Treatment of Concurrent Minimal Change Disease and Epstein Barr Virus–Driven Post-transplant Lymphoproliferative Disorder With Rituximab Following Hematopoietic Stem Cell Transplan... по Ainley, Louise, Law, Steven, Heptinstall, Lauren, Rodriguez-Justo, Manuel, Thomson, Kirsty, Pepper, Ruth J.
Опубликовано 2020Текст -
3
Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis по Ravichandran, Sriram, Law, Steven, Mahmood, Shameem, Wisniowski, Brenden, Foard, Darren, Fontana, Marianna, Martinez-Naharro, Ana, Whelan, Carol, Gillmore, Julian D., Lachmann, Helen J., Hawkins, Philip N., Wechalekar, Ashutosh D.
Опубликовано 2022Текст -
4
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib по Ravichandran, Sriram, Cohen, Oliver C., Law, Steven, Foard, Darren, Fontana, Marianna, Martinez-Naharro, Ana, Whelan, Carol, Gillmore, Julian D., Lachmann, Helen J., Sachchithanantham, Sajitha, Mahmood, Shameem, Hawkins, Philip N., Wechalekar, Ashutosh D.
Опубликовано 2021Текст -
5
The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis по Cohen, Oliver C., Law, Steven, Lachmann, Helen J., Sharpley, Faye, Ravichandran, Sriram, Mahmood, Shameem, Sachchithanantham, Sajitha, Whelan, Carol J., De Azcona Naharro, Ana Martinez, Fontana, Marianna, Hawkins, Philip N., Gillmore, Julian D., Wechalekar, Ashutosh D.
Опубликовано 2020Текст -
6
Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage по Law, Steven, Petrie, Aviva, Chacko, Liza, Cohen, Oliver C., Ravichandran, Sriram, Gilbertson, Janet A., Rowczenio, Dorota, Wechalekar, Ashutosh, Martinez‐Naharro, Ana, Lachmann, Helen J., Whelan, Carol J., Hutt, David F., Hawkins, Philip N., Fontana, Marianna, Gillmore, Julian D.
Опубликовано 2020Текст -
7
Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy по Law, Steven, Petrie, Aviva, Chacko, Liza, Cohen, Oliver C, Ravichandran, Sriram, Gilbertson, Janet A, Rowczenio, Dorota, Wechalekar, Ashutosh D, Martinez-Naharro, Ana, Lachmann, Helen J, Whelan, Carol J, Hutt, David F, Hawkins, Philip N, Fontana, Marianna, Gillmore, Julian D
Опубликовано 2022Текст -
8
Characteristics and natural history of early-stage cardiac transthyretin amyloidosis по Law, Steven, Bezard, Melanie, Petrie, Aviva, Chacko, Liza, Cohen, Oliver C, Ravichandran, Sriram, Ogunbiyi, Olabisi, Kharoubi, Mounira, Ganeshananthan, Sashiananthan, Ganeshananthan, Sharmananthan, Gilbertson, Janet A, Rowczenio, Dorota, Wechalekar, Ashutosh, Martinez-Naharro, Ana, Lachmann, Helen J, Whelan, Carol J, Hutt, David F, Hawkins, Philip N, Damy, Thibaud, Fontana, Marianna, Gillmore, Julian D
Опубликовано 2022Текст